SANOFICONR · NSE
Sanofi Consumer Healthcare India Limited
₹3,442.4
-1.49% (-₹52.1)
Prev. close
₹3,494.5
Volume
4,811
Delivery %
56.5%
As of
20 Nov 2026
Price history
Analyst sentiment
Analysts are split
1 analyst stance · last 90 days · one per analyst
Trackable
none in range
Long-Horizon
none in range
Commentary
1 · 0 bull / 1 neutral / 0 bear
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
Market commentary · 1 · levels, conditionals, previews, macro & hedged views — context, not graded
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Neutral on Sanofi Consumer shares, advising against chasing the immediate post-results rally. Investors should wait for …” | Gaurav GargLemonn | Sanofi Consumer Healthcare India Limited | — |
Fundamentals
About Sanofi Consumer Healthcare India Limited
Sanofi Consumer Healthcare India Limited operates as a fast-moving consumer healthcare company in India. The company offers products in the allergy, physical wellness, and pain care segments under Allegra, Combiflam, Avil, DePURA, Festal, and other brand names through distributors, wholesalers, government institutions and hospitals, pharmacy chains, and e-commerce platforms. The company was incorporated in 2023 and is based in Mumbai, India. Sanofi Consumer Healthcare India Limited operates as a subsidiary of Opella Healthcare Participations B.V.
Details
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Mr. Himanshu Bakshi
Headquarters
Mumbai
Employees
597
Exchange
View on NSE ↗Key stats
Market cap
₹8,009.03 Cr
P/E ratio (TTM)
28.6
Dividend yield
2.15%
EPS (TTM)
₹121.44
Beta (1Y · daily vs NIFTY 50)
0.56
Shares float
65.73 L
EPS · quarter ended Sept 2026
₹33.26
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: January–December (calendar year — this company reports on a December year-end), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
Left off as not meaningful (growth from a very small base, beyond ±400%): Fixed assets FY24 (+1260%).
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| ₹544.30 Cr | ₹724.50 Cr | ₹878.40 Cr | |
EBITDA | ₹221.30 Cr | ₹255.20 Cr | ₹334.00 Cr |
| ₹164.90 Cr | ₹181.00 Cr | ₹240.10 Cr | |
Diluted EPS | ₹71.6 | ₹78.59 | ₹104.27 |
Total expenses (as filed), Employee benefit expense, Other expenses, Other income have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| ₹345.40 Cr | ₹431.30 Cr | ₹547.00 Cr | |
| ₹0 | ₹20.30 Cr | ₹24.80 Cr | |
Stockholders' equity | ₹207.60 Cr | ₹273.00 Cr | ₹384.00 Cr |
CWIP, Others, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| ₹-40.00 L | ₹439.00 Cr | ₹174.80 Cr | |
Investing cash flow | ₹0 | ₹1.90 Cr | ₹-7.60 Cr |
| ₹2.00 Cr | ₹-115.60 Cr | ₹-134.50 Cr | |
Capital expenditure | ₹-4.00 Cr | ₹-9.90 Cr | ₹-7.60 Cr |
End cash position | ₹1.60 Cr | ₹326.90 Cr | ₹374.80 Cr |
Dividends paid has filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 24–Mar 25(5Q) | Jun 25–Jun 26(5Q) |
|---|---|---|
| Promoter | 60.40% | 71.27% |
| Public | 39.60% | 28.73% |
| Employee trusts | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Sanofi Consumer Healthcare India Limited | ₹8,062.76 Cr | ₹3,472.6 | 28.8 | 21.00 | 62.5% | 0.06 | +22.6% | -28.9% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Sanofi Consumer Healthcare Q3 results: Profit rises 22% to ₹77 crore as revenue grows 12%
Sanofi Consumer Healthcare India reported a 22.2% rise in consolidated profit to ₹77 crore for the September quarter, with revenue from operations growing 12.4% to ₹263 crore. This growth was driven by higher volumes and market share gains across key brands. Domestic sales increased by 19% year-on-year.
Medico Remedies among 5 Healthcare stocks hitting 52-week low; slipped up to 48% in a month
The Economic Times · 2 months ago